Seventeen children with acute myelocytic leukemia were treated with a combination of 6-azauridine, 6-mercaptopurine, and vincristine. Twelve attained complete bone marrow remission, and 2 achieved good partial remissions. For maintenance therapy, patients who attained remission were randomized into 2 groups: one received 6-mercaptopurine alone; the other received a combination of 6-mercaptopurine, 6-azauridine, and vincristine. The median duration of hematologic remission in these groups was 7 and 6 months, respectively. Meningeal leukemia developed in 8 of 15 patients. The overall median survival time was 8 months; for those who attained remission it was 10.5 months. The combination of 6-azauridine, 6-mercaptopurine, and vincristine was effective for remission induction of acute myelocytic leukemia in children.
No takes yet. Share an insight, caveat, or question.
Walters et al. (1972) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: